Same news, different lens. We cut through the noise and hand you the overlooked ideas and the deeper read the crowd misses. Join 38,000+ investors seeing the markets differently.

We use cookies

Value The Markets uses cookies to run the site, understand how it is used and to fund our free content with advertising. You can choose which optional cookies to allow.

See our Privacy Policy for details of the cookies we use and how we use your data.

Customize

Essential cookies

There are some cookies that we have to include in order for certain web pages to function. For this reason, they do not require your consent.

vtm_cookie_consent

1 year

Used to store the user's cookie consent preferences.
value_the_markets_session

2 hours

Used to identify the user's browsing session.
XSRF-TOKEN

2 hours

Used to secure both the user and our website against cross-site request forgery attacks.

More details

Analytics cookies

We use these for internal research on how we can improve the service we provide for all our users. These cookies assess how you interact with our website.

_ga

1 year

Main cookie used by Google Analytics, enables a service to distinguish one visitor from another.
_ga_*

1 year

Used by Google Analytics to persist session state.
_gid

1 day

Used by Google Analytics to identify the user.

More details

Advertising cookies

Set by Google AdSense to serve and measure the adverts that keep our content free. Without them no adverts are shown.

__gads

1 year

Used by Google AdSense to deliver and measure adverts.
__gpi

1 year

Used by Google AdSense to personalise adverts.
IDE

1 year

Used by Google DoubleClick to measure advert performance.

More details

Articles

Tickers

Articles

Tickers

Articles

Tickers

NanoViricides

About NanoViricides

Latest NanoViricides Press Releases

As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides

NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials

Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials

A sharper way to see the markets in just 5 minutes.